成大生物(688739) - 2025 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2025 was ¥389,109,365.95, a decrease of 7.79% compared to the same period last year[3] - The total profit for the period was ¥65,186,981.20, down 50.99% year-on-year[3] - The net profit attributable to shareholders was ¥42,517,342.30, reflecting a decline of 61.17% compared to the previous year[3] - The basic earnings per share for the period was ¥0.10, a decrease of 62.96% year-on-year[4] - Total operating revenue for the first three quarters of 2025 was ¥1,095,886,627.32, a decrease of 15.9% compared to ¥1,302,689,599.82 in the same period of 2024[18] - Net profit for the first three quarters of 2025 was ¥164,812,017.55, down 50.0% from ¥329,698,128.04 in the same period of 2024[19] - Basic and diluted earnings per share decreased to ¥0.40 from ¥0.80, reflecting a 50.0% decline[20] - The net profit for the first three quarters of 2025 was CNY 272,711,795.18, down 42.3% from CNY 472,995,635.30 in the first three quarters of 2024[28] Research and Development - Research and development expenses totaled ¥116,458,959.65, accounting for 29.93% of operating revenue, an increase of 3.08 percentage points[4] - The company experienced intensified competition in the domestic vaccine market, impacting revenue and increasing R&D expenses[8] - Research and development expenses increased slightly to ¥210,301,914.79 from ¥207,277,477.75, reflecting a growth of 1.0%[18] - Research and development expenses for the first three quarters of 2025 were CNY 163,365,806.38, an increase of 31.9% compared to CNY 123,849,598.01 in the same period of 2024[27] Cash Flow and Liquidity - The net cash flow from operating activities for the year-to-date was ¥171,017,980.98, down 41.27% compared to the previous year[3] - Cash flow from operating activities generated a net amount of ¥171,017,980.98, down 41.3% from ¥291,178,061.86 in the previous year[23] - The company's cash flow from operating activities for the first three quarters of 2025 showed a net decrease of CNY 486,398,395.41 compared to a decrease of CNY 283,688,805.57 in the same period of 2024[24] - The total cash inflow from operating activities was ¥1,042,989,241.62 in 2025, a decrease of 16.8% from ¥1,254,326,005.47 in 2024[30] - The cash and cash equivalents at the end of September 2025 were CNY 4,011,653,051.38, down from CNY 4,260,916,535.96 at the end of 2024[24] - The company's cash and cash equivalents decreased to RMB 4,010,183,067.13 from RMB 4,496,464,173.92, representing a decline of 10.83%[13] Assets and Liabilities - The total assets at the end of the period were ¥9,802,754,278.51, a decrease of 2.48% from the end of the previous year[4] - The total liabilities decreased to RMB 415,573,793.76 from RMB 489,119,315.20, a reduction of 15.04%[16] - The total equity attributable to shareholders was ¥9,387,180,484.75, a decrease of 1.83% from the previous year-end[4] - The company's total current assets as of September 30, 2025, were CNY 7,065,602,021.25, a decrease from CNY 7,248,416,940.65 at the end of 2024[24] - The total assets as of September 30, 2025, amounted to CNY 10,212,076,773.29, a decrease from CNY 10,347,110,363.62 at the end of 2024[26] Investment Activities - Cash inflow from investment activities totaled ¥3,526,438,967.31, an increase from ¥3,205,987,693.27 in the same period of 2024[23] - Cash outflow from investment activities increased to ¥3,841,337,519.09 from ¥3,398,435,517.05, resulting in a net cash flow of -¥314,898,551.78[23] - The net cash flow from investment activities was -¥323,005,037.69 in 2025, compared to -¥281,258,222.92 in 2024, indicating a worsening position[30] - Total cash inflow from investment activities in 2025 was ¥3,353,272,988.02, an increase of 12.4% from ¥2,984,090,714.51 in 2024[30] Shareholder Information - The total equity attributable to shareholders decreased to RMB 9,387,180,484.75 from RMB 9,562,467,951.11, a decrease of 1.83%[16] - The company held 5,199,548 shares in its repurchase account, accounting for 1.25% of the total share capital as of September 30, 2025[11] Accounting Standards - The company will not apply new accounting standards starting from 2025[32]